This HTML5 document contains 60 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
dctermshttp://purl.org/dc/terms/
n20http://localhost/temp/predkladatel/
n11http://linked.opendata.cz/resource/domain/vavai/projekt/
n7http://linked.opendata.cz/resource/domain/vavai/riv/tvurce/
n16http://linked.opendata.cz/ontology/domain/vavai/
shttp://schema.org/
skoshttp://www.w3.org/2004/02/skos/core#
rdfshttp://www.w3.org/2000/01/rdf-schema#
n3http://linked.opendata.cz/ontology/domain/vavai/riv/
n14http://bibframe.org/vocab/
n2http://linked.opendata.cz/resource/domain/vavai/vysledek/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n18http://linked.opendata.cz/resource/domain/vavai/vysledek/RIV%2F00216224%3A14740%2F14%3A00074752%21RIV15-MSM-14740___/
n5http://linked.opendata.cz/ontology/domain/vavai/riv/klicoveSlovo/
n19http://linked.opendata.cz/ontology/domain/vavai/riv/duvernostUdaju/
xsdhhttp://www.w3.org/2001/XMLSchema#
n15http://linked.opendata.cz/ontology/domain/vavai/riv/aktivita/
n12http://linked.opendata.cz/ontology/domain/vavai/riv/jazykVysledku/
n17http://linked.opendata.cz/ontology/domain/vavai/riv/druhVysledku/
n4http://linked.opendata.cz/ontology/domain/vavai/riv/obor/
n8http://reference.data.gov.uk/id/gregorian-year/

Statements

Subject Item
n2:RIV%2F00216224%3A14740%2F14%3A00074752%21RIV15-MSM-14740___
rdf:type
skos:Concept n16:Vysledek
rdfs:seeAlso
http://onlinelibrary.wiley.com/doi/10.1002/hon.2091/abstract
dcterms:description
This multicentre study focused on monitoring imatinib mesylate(IMA)trough plasma(Ctrough) and intracellular (IMA Cintrac) concentrations in 228 chronic myelogenous leukaemia patients. We found a correlation between IMA Ctrough and alpha 1-acid glycoprotein plasma concentrations. All other analysed parameters revealed only weak (gender, dose of IMA per kg) or not significant (age, albumin, creatinine plasma concentration or bodymass index) impact onmeasured IMA Ctrough. The IMA Ctrough decreased during the first 6months and significantly increased later during treatment. The IMA Ctrough at the first month of therapy did not differ between patients with and without an optimal response at the 12th (p = 0.724) and 18th month (p = 0.135) of therapy. The IMA Cintrac during the first month were not different between patients with and without an optimal response at the 6th (p=0.273) and the 12th month (p = 0.193) of therapy. This multicentre study focused on monitoring imatinib mesylate(IMA)trough plasma(Ctrough) and intracellular (IMA Cintrac) concentrations in 228 chronic myelogenous leukaemia patients. We found a correlation between IMA Ctrough and alpha 1-acid glycoprotein plasma concentrations. All other analysed parameters revealed only weak (gender, dose of IMA per kg) or not significant (age, albumin, creatinine plasma concentration or bodymass index) impact onmeasured IMA Ctrough. The IMA Ctrough decreased during the first 6months and significantly increased later during treatment. The IMA Ctrough at the first month of therapy did not differ between patients with and without an optimal response at the 12th (p = 0.724) and 18th month (p = 0.135) of therapy. The IMA Cintrac during the first month were not different between patients with and without an optimal response at the 6th (p=0.273) and the 12th month (p = 0.193) of therapy.
dcterms:title
No clinical evidence for performing trough plasma and intracellular imatinib concentrations monitoring in patients with chronic myelogenous leukaemia No clinical evidence for performing trough plasma and intracellular imatinib concentrations monitoring in patients with chronic myelogenous leukaemia
skos:prefLabel
No clinical evidence for performing trough plasma and intracellular imatinib concentrations monitoring in patients with chronic myelogenous leukaemia No clinical evidence for performing trough plasma and intracellular imatinib concentrations monitoring in patients with chronic myelogenous leukaemia
skos:notation
RIV/00216224:14740/14:00074752!RIV15-MSM-14740___
n3:aktivita
n15:P
n3:aktivity
P(ED1.1.00/02.0068)
n3:cisloPeriodika
2
n3:dodaniDat
n8:2015
n3:domaciTvurceVysledku
n7:4376285 n7:3715434 n7:1344153 n7:4568567 n7:6563902 n7:8780757
n3:druhVysledku
n17:J
n3:duvernostUdaju
n19:S
n3:entitaPredkladatele
n18:predkladatel
n3:idSjednocenehoVysledku
32673
n3:idVysledku
RIV/00216224:14740/14:00074752
n3:jazykVysledku
n12:eng
n3:klicovaSlova
CML; imatinib; plasma concentration; cell-asscociated concentration
n3:klicoveSlovo
n5:CML n5:plasma%20concentration n5:imatinib n5:cell-asscociated%20concentration
n3:kodStatuVydavatele
US - Spojené státy americké
n3:kontrolniKodProRIV
[BD9476DC3EEF]
n3:nazevZdroje
Hematological Oncology
n3:obor
n4:FD
n3:pocetDomacichTvurcuVysledku
6
n3:pocetTvurcuVysledku
15
n3:projekt
n11:ED1.1.00%2F02.0068
n3:rokUplatneniVysledku
n8:2014
n3:svazekPeriodika
32
n3:tvurceVysledku
Malakova, Jana Klamova, Hana Malásková, Ludmila Zdráhal, Zbyněk Voglová, Jaroslava Rázga, Filip Belohlavkova, Petra Polakova, Katerina Machova Dyr, Jan Mužík, Jan Suttnar, Jiří Ráčil, Zdeněk Žáčková, Daniela Potěšil, David Mayer, Jiří
n3:wos
000340570100005
s:issn
0278-0232
s:numberOfPages
7
n14:doi
10.1002/hon.2091
n20:organizacniJednotka
14740